GLI1 and neoplasm: Overall, no significant association was observed between extent of GLI1 inhibition and time to tumor response (TTR), with HR (95% CI, P-value) for low vs high expression of 0.9 (0.4–1.9, P = 0.4932) and 1.4 (0.7–2.8, P = 0.3148) for the 200 and 800 mg groups, respectively (Supplementary Table 4).